ScreenerHero

KLRSKalaris Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · kalaristx.com
4.150USD-0.48%Mkt Cap: 98.79M $P/E: —

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular end…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap98.79M $
Enterprise Value5.94M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-43.44M $
Revenue/Share—
Last Price4.150 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.48
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.70
EPS (TTM)-1.85
EPS (Forward)-1.66
52W Range
2.36019% of range11.88
52W High11.88 USD
52W Low2.360 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-55.11%
ROA-35.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-38.37M $
CapEx (TTM)200.00K $
FCF Margin—
FCF Yield-26.56%
Net Debt-92.14M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.02
Current Ratio10.98
Quick Ratio10.71
Book Value/Sh2.423 USD
Cash/Share3.929 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:23
Split DateJan 16, 2025
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.71 USD
Upside (mean)+350.9%
Target Range7.000 USD – 25.00 USD
$7.000+350.9% to mean$25.00
# Analysts7
Ownership
Shares Out.23.80M
Float7.25M
Insiders8.81%
Institutions75.72%
Short Interest
Short Ratio0.7d
Short % Float4.95%
Short % Out.1.73%
Shares Short411.65K
Short (prev mo.)502.58K
Technical
SMA 504.202 (-1.2%)
SMA 2006.491 (-36.1%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)456.02K
Avg Vol (10d)46.24K
Technical Indicators
RSI (14)52.1
MACD-0.0397
MACD Signal-0.0889
MACD Hist.+0.0491
BB Upper4.474 USD
BB Middle3.893 USD
BB Lower3.313 USD
BB Width29.80%
ATR (14)0.3371 USD
Vol Ratio (20d)1.04x